Spinal endomorphins attenuate burn-injury pain in male mice by inhibiting p38 MAPK signaling pathway through the mu-opioid receptor

Eur J Pharmacol. 2021 Jul 15:903:174139. doi: 10.1016/j.ejphar.2021.174139. Epub 2021 Apr 30.

Abstract

Burn injury is one of the main causes of mortality worldwide and frequently associated with severe and long-lasting pain that compromises the quality of patient life. Several studies have shown that the mu-opioid system plays an important role in burn pain relief. In this study, we investigated the spinal antinociception induced by the endogenous mu-opioid receptor (MOR) agonists endomorphins and explored their mechanisms of actions in burn injury-induced pain model. Our results showed that intrathecal injection of endomorphin-1 and -2 dose-dependently attenuated mechanical allodynia and thermal hyperalgesia via the mu-opioid receptor in mice on day 3 after burn injury, which was consistent with the data obtained from the mu-opioid receptor knockout mice. Western blot showed that the phosphorylation levels of extracellular signal-regulated kinase1/2 (ERK1/2) and p38 mitogen-activated protein kinase (p38 MAPK) in ipsilateral spinal cord tissues were significantly up-regulated after burn injury. Intrathecal injection of endomorphins selectively inhibited the activation of p38 MAPK on day 3 after burn injury via the mu-opioid receptor. Further studies found that repeated application of the specific p38 MAPK inhibitor SB203580 dose-dependently inhibited burn-injury pain, as well as the activation of spinal p38 MAPK. Taken together, our present study demonstrates that intrathecal injection of endomorphins attenuates burn-injury pain in male mice by affecting the spinal activation of p38 MAPK via the mu-opioid receptor.

Keywords: Burn injury-induced pain; ERK1/2; Endomorphins; Mu-opioid receptor; p38 MAPK.

MeSH terms

  • Analgesics, Opioid / administration & dosage
  • Analgesics, Opioid / pharmacology*
  • Animals
  • Behavior, Animal / drug effects
  • Burns / complications
  • Burns / drug therapy*
  • Burns / metabolism
  • Disease Models, Animal
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Hyperalgesia / drug therapy
  • Imidazoles / pharmacology
  • Imidazoles / therapeutic use
  • Injections, Spinal
  • Male
  • Mice
  • Mice, Knockout
  • Narcotic Antagonists / pharmacology
  • Narcotic Antagonists / therapeutic use
  • Oligopeptides / administration & dosage
  • Oligopeptides / pharmacology*
  • Pain / drug therapy*
  • Pain / etiology
  • Pain / metabolism
  • Pyridines / pharmacology
  • Pyridines / therapeutic use
  • Receptors, Opioid, mu / genetics
  • Receptors, Opioid, mu / metabolism*
  • Signal Transduction / drug effects
  • Spinal Cord Injuries / drug therapy
  • Spinal Cord Injuries / etiology
  • Spinal Cord Injuries / metabolism
  • p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors*
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Analgesics, Opioid
  • Enzyme Inhibitors
  • Imidazoles
  • Narcotic Antagonists
  • Oligopeptides
  • Pyridines
  • Receptors, Opioid, mu
  • endomorphin 1
  • endomorphin 2
  • p38 Mitogen-Activated Protein Kinases
  • SB 203580